ATE543497T1 - Substituierte heterozyklische derivate als mittel gegen diabetes und adipositas und verfahren - Google Patents

Substituierte heterozyklische derivate als mittel gegen diabetes und adipositas und verfahren

Info

Publication number: ATE543497T1
Authority: AT; Austria
Prior art keywords: obesity; methods; substituted heterocyclic; agent against; heterocyclic derivatives
Prior art date: 2002-07-09

Application number

AT03763345T

Other languages

English (en)

Inventor

Peter Cheng

Sean Chen

Charles Ding

Timothy Herpin

Original Assignee

Bristol Myers Squibb Co

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2002-07-09

Filing date

2003-07-08

Publication date

2012-02-15

2003-07-08 Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co

2012-02-15 Application granted granted Critical

2012-02-15 Publication of ATE543497T1 publication Critical patent/ATE543497T1/de

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/64—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
- C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D249/04—1,2,3-Triazoles; Hydrogenated 1,2,3-triazoles
- C07D249/06—1,2,3-Triazoles; Hydrogenated 1,2,3-triazoles with aryl radicals directly attached to ring atoms
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
- C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
- C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D263/32—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
- C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
- C07D271/06—1,2,4-Oxadiazoles; Hydrogenated 1,2,4-oxadiazoles
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Health & Medical Sciences (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Diabetes (AREA)
Obesity (AREA)
Hematology (AREA)
Pain & Pain Management (AREA)
Cardiology (AREA)
Emergency Medicine (AREA)
Endocrinology (AREA)
Vascular Medicine (AREA)
Heart & Thoracic Surgery (AREA)
Urology & Nephrology (AREA)
Rheumatology (AREA)
Child & Adolescent Psychology (AREA)
Dermatology (AREA)
Physical Education & Sports Medicine (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Plural Heterocyclic Compounds (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

AT03763345T 2002-07-09 2003-07-08 Substituierte heterozyklische derivate als mittel gegen diabetes und adipositas und verfahren ATE543497T1 (de)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US39455302P	2002-07-09	2002-07-09
PCT/US2003/021331 WO2004004655A2 (en)	2002-07-09	2003-07-08	Substituted heterocyclic derivatives useful as antidiabetic and antiobesity agents and method

Publications (1)

Publication Number	Publication Date
ATE543497T1 true ATE543497T1 (de)	2012-02-15

Family

ID=30115733

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT03763345T ATE543497T1 (de)	2002-07-09	2003-07-08	Substituierte heterozyklische derivate als mittel gegen diabetes und adipositas und verfahren

Country Status (23)

Country	Link
US (2)	US6875782B2 (de)
EP (1)	EP1531810B1 (de)
JP (1)	JP4541883B2 (de)
KR (1)	KR101120337B1 (de)
CN (1)	CN1665500A (de)
AT (1)	ATE543497T1 (de)
AU (1)	AU2003248861B2 (de)
BR (1)	BR0312503A (de)
CA (1)	CA2490972C (de)
ES (1)	ES2380319T3 (de)
GE (1)	GEP20084475B (de)
HR (1)	HRP20050001A2 (de)
IL (1)	IL165809A (de)
IS (1)	IS7629A (de)
MX (1)	MXPA05000279A (de)
NO (1)	NO329328B1 (de)
NZ (1)	NZ537251A (de)
PL (1)	PL375230A1 (de)
RS (1)	RS20050002A (de)
RU (1)	RU2325381C2 (de)
UA (1)	UA79296C2 (de)
WO (1)	WO2004004655A2 (de)
ZA (1)	ZA200500029B (de)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
ATE372770T1 (de) *	2002-08-01	2007-09-15	Neurosearch As	Verbindungen nützlich in der behandlung von erkrankungen die auf anti-angiogenertherapie antworten
MY142651A (en)	2003-03-18	2010-12-15	Merck Sharp & Dohme	Biaryl substituted triazoles as sodium channel blockers
US20060183897A1 (en) *	2003-03-18	2006-08-17	Chakravarty Prasun K	Biaryl substituted triazoles as sodium channel blockers
CA2518465A1 (en)	2003-03-25	2004-10-14	Takeda San Diego, Inc.	Dipeptidyl peptidase inhibitors
JP2007511467A (ja)	2003-05-14	2007-05-10	タケダサンディエゴインコーポレイテッド	ジペプチジルペプチダーゼインヒビター
KR20060041309A (ko)	2003-08-13	2006-05-11	다케다 야쿠힌 고교 가부시키가이샤	４-피리미돈 유도체 및 펩티딜 펩티다제 저해제로서의 그의용도
FR2861303A1 (fr) *	2003-10-24	2005-04-29	Sanofi Synthelabo	Utilisation d'un derive de pyrazole pour la preparation de medicaments utiles dans la prevention et le traitement du syndrome metabolique
FR2861300B1 (fr) *	2003-10-24	2008-07-11	Sanofi Synthelabo	Utilisation d'un derive du pyrazole, pour la preparation de medicaments utiles dans la prevention et le traitement du syndrome metabolique
FR2861301B1 (fr) *	2003-10-24	2008-07-11	Sanofi Synthelabo	Utilisation du derive du pyrazole pour la preparation de medicaments utiles dans la prevention et le traitement du syndrome metabolique.
FR2861302A1 (fr) *	2003-10-24	2005-04-29	Sanofi Synthelabo	Utilisation d'un derive du pyrazole, pour la preparation de medicaments utiles dans la prevention et le traitement du syndrome metabolique.
CN1882327A (zh) *	2003-11-19	2006-12-20	症变治疗公司	含磷的新的拟甲状腺素药
KR101494067B1 (ko)	2004-03-05	2015-02-16	더 트러스티스 오브 더 유니버시티 오브 펜실바니아	부작용을 최소화하면서 과지질혈증 및 과콜레스테롤혈증과 연관된 질환 또는 질병의 치료 방법
WO2005115384A2 (en) *	2004-05-25	2005-12-08	Metabolex, Inc.	Bicyclic, substituted triazoles as modulators of ppar and methods of their preparation
CN1997633A (zh) *	2004-05-25	2007-07-11	麦它波莱克斯股份有限公司	作为ppar调节剂的取代的三唑及其制备方法
WO2006032042A2 (en) *	2004-09-15	2006-03-23	Regeneron Pharmaceuticals, Inc.	Us of cntf or a cntf derivative in combination with a further compound for the preparation of medicament for the treatment of obesity
EP1807070A1 (de) *	2004-09-29	2007-07-18	Schering Corporation	Kombinationen aus substituierten azetidinonen und cb1-antagonisten
EP1866298A2 (de) *	2005-03-31	2007-12-19	Takeda San Diego, Inc.	Hydroxysteroiddehydrogenase-hemmer
WO2006117743A1 (en) *	2005-05-03	2006-11-09	Ranbaxy Laboratories Limited	Substituted aromatic compounds as antidiabetic agents
WO2006128056A2 (en) *	2005-05-26	2006-11-30	Metabasis Therapeutics, Inc.	Novel phosphinic acid-containing thyromimetics
MX2007014502A (es)	2005-05-26	2008-02-07	Metabasis Therapeutics Inc	Tiromimeticos para el tratamiento de enfermedades del higado graso.
FR2889191A1 (fr) *	2005-07-28	2007-02-02	Cerep Sa	Composes derives de 5-benzylidene imidazolidine 2,4-dione et leur utilisation en tant qu'antagonistes de mchr-1
MY147393A (en)	2005-09-14	2012-11-30	Takeda Pharmaceutical	Administration of dipeptidyl peptidase inhibitors
CA2622642C (en)	2005-09-16	2013-12-31	Takeda Pharmaceutical Company Limited	Dipeptidyl peptidase inhibitors
AU2006304689A1 (en) *	2005-10-18	2007-04-26	Aegerion Pharmaceuticals	Compositions for lowering serum cholesterol and/or triglycerides
MX2008015228A (es) *	2006-05-30	2008-12-12	Astrazeneca Ab	Acido 5-fenilamino-1,3,4-oxadiazol-2-ilcarbonilamino-4-fenoxi-cicl ohexanocarboxilico sustituido como inhibidor de diacilglicerol aciltransferasa de acetil coenzima a.
CN101460470B (zh) *	2006-05-30	2011-05-18	阿斯利康(瑞典)有限公司	作为dgat1抑制剂的1,3,4-二唑衍生物
US20080009534A1 (en) *	2006-07-07	2008-01-10	Bristol-Myers Squibb Company	Substituted acid derivatives useful as antidiabetic and antiobesity agents and method
US8324383B2 (en)	2006-09-13	2012-12-04	Takeda Pharmaceutical Company Limited	Methods of making polymorphs of benzoate salt of 2-[[6-[(3R)-3-amino-1-piperidinyl]-3,4-dihydro-3-methyl-2,4-dioxo-1(2H)-pyrimidinyl]methyl]-benzonitrile
US8217025B2 (en) *	2006-11-17	2012-07-10	Harbor Therapeutics, Inc.	Drug screening and treatment methods
TW200838536A (en)	2006-11-29	2008-10-01	Takeda Pharmaceutical	Polymorphs of succinate salt of 2-[6-(3-amino-piperidin-1-yl)-3-methyl-2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-ylmethy]-4-fluor-benzonitrile and methods of use therefor
JP2010513534A (ja) *	2006-12-21	2010-04-30	エージェリオンファーマシューティカルズ，インコーポレイテッド	Ｍｔｐインヒビターおよびコレステロール吸収インヒビターを含む組み合わせを用いて肥満症を処置する方法
US8093236B2 (en)	2007-03-13	2012-01-10	Takeda Pharmaceuticals Company Limited	Weekly administration of dipeptidyl peptidase inhibitors
TW200906823A (en)	2007-07-16	2009-02-16	Lilly Co Eli	Compounds and methods for modulating FXR
US8652527B1 (en)	2013-03-13	2014-02-18	Upsher-Smith Laboratories, Inc	Extended-release topiramate capsules
US9101545B2 (en)	2013-03-15	2015-08-11	Upsher-Smith Laboratories, Inc.	Extended-release topiramate capsules
CN103694195B (zh) *	2013-09-18	2016-04-06	华东师范大学	芳香杂环类小分子有机化合物及衍生物、制备方法及医药用途
EP3190103A1 (de) *	2016-01-08	2017-07-12	Rijksuniversiteit Groningen	Inhibitoren der pd-1/pd-l1-protein-/proteinwechselwirkung
JP2020500199A (ja)	2016-11-21	2020-01-09	バイキング・セラピューティクス・インコーポレイテッド	グリコーゲン蓄積症の治療方法
AU2018280118B2 (en)	2017-06-05	2021-07-15	Viking Therapeutics, Inc.	Compositions for the treatment of fibrosis
KR101943382B1 (ko)	2017-09-19	2019-01-29	오토텔릭바이오 주식회사	Sglt-2 저해제 및 안지오텐신 수용체 차단제를 포함하는 의약 조성물
ES3053674T3 (en)	2018-03-22	2026-01-23	Viking Therapeutics Inc	Crystalline forms and methods of producing crystalline forms of a compound
GB201810486D0 (en) *	2018-06-26	2018-08-08	Imperial Innovations Ltd	Natural killer cells
KR102131359B1 (ko) *	2018-09-07	2020-07-07	오토텔릭바이오 주식회사	안정성이 향상된 의약 조성물
WO2020117962A1 (en)	2018-12-05	2020-06-11	Viking Therapeutics, Inc.	Compositions for the treatment of fibrosis and inflammation
CA3186856A1 (en)	2020-07-29	2022-02-03	Ruth NALLEN	Lomitapide for use in methods of treating hyperlipidemia and hypercholesterolemia in pediatric patients

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE69427023T2 (de)	1993-12-28	2001-10-31	Meiji Seika K.K., Tokio/Tokyo	Tricyclische benzazepin-und benzothiazepin derivate
JPH10501222A (ja) *	1994-05-27	1998-02-03	メルクエンドカンパニーインコーポレーテッド	破骨細胞仲介骨吸収を抑制するための化合物
JP3537446B2 (ja)	1995-06-15	2004-06-14	明治製菓株式会社	三環性ベンゾアゼピン化合物
GB9604242D0 (en) *	1996-02-28	1996-05-01	Glaxo Wellcome Inc	Chemical compounds
JP3215048B2 (ja) *	1996-04-03	2001-10-02	日本たばこ産業株式会社	プロピオン酸誘導体及びその用途
JPH1067759A (ja)	1996-06-20	1998-03-10	Sankyo Co Ltd	除草性アゾール誘導体
JPH11263775A (ja)	1997-09-08	1999-09-28	Sankyo Co Ltd	ヒドロキシアニリン誘導体
ES2191963T3 (es)	1997-09-29	2003-09-16	Meiji Seika Kaisha	Derivados triciclicos de triazolobenzazepina, proceso para la obtencion de los mismos y agentes antialergicos.
ATE451346T1 (de) *	1998-03-10	2009-12-15	Ono Pharmaceutical Co	Carbonsäurederivate und medikamente die diese als aktiven wirkstoff enthalten
FR2778314B1 (fr)	1998-05-07	2002-06-14	Rhone Poulenc Agrochimie	Composition fongicide synergique comprenant un compose analogue de la strobilurine
GB9914977D0 (en) *	1999-06-25	1999-08-25	Glaxo Group Ltd	Chemical compounds
ATE260912T1 (de)	1999-09-08	2004-03-15	Glaxo Group Ltd	Oxazol ppar antagonisten
TWI302149B (en) *	1999-09-22	2008-10-21	Bristol Myers Squibb Co	Substituted acid derivatives useful as antiodiabetic and antiobesity agents and method
US6414002B1 (en)	1999-09-22	2002-07-02	Bristol-Myers Squibb Company	Substituted acid derivatives useful as antidiabetic and antiobesity agents and method
IL149493A0 (en)	1999-11-10	2002-11-10	Takeda Chemical Industries Ltd	5-membered n-heterocyclic compounds with hypoglycemic and hypolipidemic activity
GB0029974D0 (en) *	2000-12-08	2001-01-24	Glaxo Group Ltd	Chemical compounds

2003
- 2003-07-08 BR BRPI0312503-3A patent/BR0312503A/pt not_active IP Right Cessation
- 2003-07-08 CN CN038160382A patent/CN1665500A/zh active Pending
- 2003-07-08 MX MXPA05000279A patent/MXPA05000279A/es active IP Right Grant
- 2003-07-08 CA CA2490972A patent/CA2490972C/en not_active Expired - Fee Related
- 2003-07-08 AT AT03763345T patent/ATE543497T1/de active
- 2003-07-08 PL PL03375230A patent/PL375230A1/xx not_active Application Discontinuation
- 2003-07-08 NZ NZ537251A patent/NZ537251A/en not_active IP Right Cessation
- 2003-07-08 EP EP03763345A patent/EP1531810B1/de not_active Expired - Lifetime
- 2003-07-08 JP JP2004520018A patent/JP4541883B2/ja not_active Expired - Fee Related
- 2003-07-08 KR KR1020057000362A patent/KR101120337B1/ko not_active Expired - Fee Related
- 2003-07-08 AU AU2003248861A patent/AU2003248861B2/en not_active Ceased
- 2003-07-08 RU RU2005103395/04A patent/RU2325381C2/ru not_active IP Right Cessation
- 2003-07-08 GE GEAP8617A patent/GEP20084475B/en unknown
- 2003-07-08 US US10/616,283 patent/US6875782B2/en not_active Expired - Lifetime
- 2003-07-08 ES ES03763345T patent/ES2380319T3/es not_active Expired - Lifetime
- 2003-07-08 RS YUP-2005/0002A patent/RS20050002A/sr unknown
- 2003-07-08 WO PCT/US2003/021331 patent/WO2004004655A2/en not_active Ceased
- 2003-07-08 HR HR20050001A patent/HRP20050001A2/hr not_active Application Discontinuation
- 2003-08-07 UA UAA200501187A patent/UA79296C2/uk unknown
2004
- 2004-12-16 IL IL165809A patent/IL165809A/en not_active IP Right Cessation
- 2004-12-17 NO NO20045529A patent/NO329328B1/no not_active IP Right Cessation
- 2004-12-17 US US11/016,183 patent/US7507757B2/en not_active Expired - Lifetime
2005
- 2005-01-03 ZA ZA200500029A patent/ZA200500029B/xx unknown
- 2005-01-05 IS IS7629A patent/IS7629A/is unknown

Also Published As

Publication number	Publication date
US20040063762A1 (en)	2004-04-01
ES2380319T3 (es)	2012-05-10
PL375230A1 (en)	2005-11-28
HRP20050001A2 (en)	2005-08-31
IS7629A (is)	2005-01-05
EP1531810A4 (de)	2008-05-28
IL165809A (en)	2010-05-17
NO329328B1 (no)	2010-09-27
BR0312503A (pt)	2007-06-26
ZA200500029B (en)	2006-06-28
AU2003248861A1 (en)	2004-01-23
RU2325381C2 (ru)	2008-05-27
IL165809A0 (en)	2006-01-15
CA2490972C (en)	2012-05-29
GEP20084475B (en)	2008-09-10
UA79296C2 (en)	2007-06-11
AU2003248861B2 (en)	2009-01-22
US20050119312A1 (en)	2005-06-02
JP4541883B2 (ja)	2010-09-08
NO20045529L (no)	2005-02-03
CA2490972A1 (en)	2004-01-15
RS20050002A (sr)	2007-09-21
EP1531810B1 (de)	2012-02-01
WO2004004655A2 (en)	2004-01-15
WO2004004655A3 (en)	2004-10-14
MXPA05000279A (es)	2005-03-31
EP1531810A2 (de)	2005-05-25
JP2006501187A (ja)	2006-01-12
US6875782B2 (en)	2005-04-05
US7507757B2 (en)	2009-03-24
CN1665500A (zh)	2005-09-07
KR101120337B1 (ko)	2012-02-29
KR20050025951A (ko)	2005-03-14
RU2005103395A (ru)	2005-08-10
NZ537251A (en)	2007-02-23

Publication	Publication Date	Title
ATE543497T1 (de)	2012-02-15	Substituierte heterozyklische derivate als mittel gegen diabetes und adipositas und verfahren
ECSP055813A (es)	2005-08-11	Quinolin-, isoquinolin- y quinazolin-oxialquilamidas y su uso como fungicidas
EP1478276A4 (de)	2006-04-19	Neue gezielte zusammensetzungen zur diagnostischen und therapeutischen verwendung
ATE447404T1 (de)	2009-11-15	Substituierte benzazole und ihre verwendung als raf-kinase-hemmer
DE60308210D1 (de)	2006-10-19	Medizinische fassvorrichtung
EP1555267A4 (de)	2010-08-18	2,3-DIHYDRO-6-NITROIMIDAZOç2,1-b]OXAZOLE
ATE510534T1 (de)	2011-06-15	Naltrexonhydrochlorid-zusammensetzungen
BRPI0417717A (pt)	2007-04-03	composto, composição farmacêutica, e, uso de um composto
DK1620437T3 (da)	2009-08-24	5,7-diaminopyrazolo-4,3-d-pyrimidiner, der er anvendelige til behandling af hypertension
WO2004004665A3 (en)	2004-03-25	Substituted heterocyclic derivatives useful as antidiabetic and antiobesity agents and method
CY1109737T1 (el)	2014-09-10	Νεα μεθοδος συνθεσης του (7-μεθοξυ-1-ναφθυλ) ακετονιτριλιου και εφαρμογη στη συνθεση της αγομελατινης
DE60304928D1 (de)	2006-06-08	Silica-gefüllte Elastomerenzusammensetzung
BRPI0417858A (pt)	2007-04-27	composto, composição farmacêutica, e, uso de uma composição farmacêutica
ATE483699T1 (de)	2010-10-15	Neue 2-arylthiazolverbindungen als ppar-alpha und gamma agonisten
NO20062629L (no)	2006-09-06	Oksazolderivater av tetrackliner
DK1558580T3 (da)	2008-01-14	N-sulfonyl-4-methylenamino-3-hydroxy-2-pyridoner
ECSP044971A (es)	2004-03-23	Isoxazolopiridinonas y su uso en el tratamiento de enfermedad de parkinson
SM200300009B (it)	2004-12-01	Composizione e suo uso terapeutico
DE60321641D1 (de)	2008-07-31	Photopolymerisierbare Initiatorkombination und photopolymerisierbare Zusammensetzung
BRPI0500536A (pt)	2005-12-06	Composição antimicrobiana
BR0316544A (pt)	2005-10-04	Compostos calcilìticos
ITMI20020624A1 (it)	2003-09-26	Composizioni ad attivita' biostimolante
HRP20050611B1 (hr)	2013-12-20	Kombinacijski lijek
ECSP056174A (es)	2006-04-19	Acidos hidroxamicos utiles en el tratamiento detrastornos hiperproliferativos
ATE456568T1 (de)	2010-02-15	Kondensierte heterocyclische isoxazolinderivate und deren verwendung als antidepressiva